Multiattribute Method Patents: Leaders & Filing Trends 2026
Multiattribute Method for Quality Control: Patents Behind the MAM Shift in Biologics QC
Concentrated at the top. The five leading assignees together hold 481 of 879 records in scope (54.7%), and the top ten hold 75.0%. Annual filings rose to a peak of 100 in 2018, held near that level through the following years, then fell from 76 in 2021 to 35 in 2024 — a 54% decline over that span. 2025 and 2026 figures are still filling in as later-filed applications publish.
- 1AMGEN RESEARCH (MUNICH) GMBH163
- 2AMGEN INC136
- 3BRISTOL MYERS SQUIBB CO67
- 4GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD60
- 5ATYR PHARM INC55
See the full multiattribute method for quality control analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about multiattribute method patents
What is the multiattribute method (MAM) in patent terms?
In this dataset, MAM patents cluster around peptide mapping, new peak detection and attribute monitoring, typically combined with chromatography and mass spectrometry method claims. Most filings anchor their claims in a biologic drug substance (C07K, A61K classes) and add the analytical method as a supporting or dependent claim. A smaller group of filers, mainly instrumentation vendors, claim the analytical methodology itself independent of any specific molecule.
Who holds the most multiattribute method patents?
The ranking covers 93 assignees, with the leading company holding 163 of the 879 records in scope and the top five together holding 481 records (54.7%). This is a concentrated field: the top ten hold 75.0% of records, leaving the remaining 83 ranked assignees to divide the balance. No single filer approaches a majority, so competitive clearance work should look at the group of leaders rather than one company.
Is multiattribute method patent filing still growing?
Filing activity peaked at 100 in 2018 and has since declined in complete-year data, falling from 76 in 2021 to 35 in 2024, a 54% drop over that span. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by about 18 months, so the true 2025-2026 volume will be higher than currently shown once those applications publish. The overall pattern to date, however, is a pullback from the 2018 peak rather than continued acceleration.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Multiattribute Method for Quality Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.